Goldman Sachs Begins Covering Magenta Therapeutics (MGTA) Stock. “Shares to Hit $18.0”

July 16, 2018 - By Matthew Richard

Why Has Goldman Sachs Given Magenta Therapeutics (MGTA) a $18.0 Price Target

Expert analysts at Goldman Sachs began coverage on shares of Magenta Therapeutics (MGTA) in a note released on 16 July. The broker set “Buy” rating on the stock. Goldman Sachs’s target price of $18.0 suggests potential of 42.86 % from the stock’s current stock price.

The stock decreased 5.69% or $0.76 during the last trading session, reaching $12.6. About 129,629 shares traded. Magenta Therapeutics, Inc. (MGTA) has 0.00% since July 16, 2017 and is . It has underperformed by 12.57% the S&P500.

Magenta Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. The company has market cap of $410.03 million. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. It currently has negative earnings. The firm was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016.

More notable recent Magenta Therapeutics, Inc. (NASDAQ:MGTA) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: Epidiolex, Roche’s Influenza Drug Gets Priority Review Status, Xeris Jumps On …” on June 26, 2018, also Benzinga.com with their article: “Benzinga’s Daily Biotech Pulse: AbbVie Launches New Pediatric Humira, IPO Deluge Hits The Street” published on June 21, 2018, Bizjournals.com published: “Goodwin dominates this year’s record batch of Mass. biotech IPOs” on July 03, 2018. More interesting news about Magenta Therapeutics, Inc. (NASDAQ:MGTA) were released by: Seekingalpha.com and their article: “Stocks To Watch: Prime Time In Retail” published on July 14, 2018 as well as Investorplace.com‘s news article titled: “8 Biotech Stocks With IPOs This Week” with publication date: June 20, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.